Omitting Routine Prophylactic Pegfilgrastim During Paclitaxel Portion Of Treatment Appears Safe And Feasible For Certain Patients With Breast Cancer Healio (7/13, Southall) reports researchers found “omitting routine prophylactic pegfilgrastim during the paclitaxel portion of treatment appeared safe and feasible for certain patients with breast cancer.” The “researchers found no causal relationship between omission of pegfilgrastim and […]
In Women With TPF3-Mutated, Platinum Sensitive Ovarian Cancer, WEE1 Kinase Inhibitor, Plus Carboplatin, Paclitaxel Improved PFS Compared With Chemo Alone Cancer Therapy Advisor (7/8, Lawrence) reports, “Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared with chemotherapy alone, according to results from a phase […]
Cancer Therapy Advisor (7/1, Primeau) reports, “Patients with human papillomavirus (HPV)-negative vulvar cancer commonly harbored TP53 mutations, according to results from a whole-exome analysis published in Gynecological Oncology.” Specifically, “sequencing identified integration of viral E7 gene from HPV 16 among 35.3% of samples; the remaining were HPV-negative.” Moreover, “the other most common nonsynonymous mutations occurred in […]